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Response to Al Sulais et al. 
 
Thomas Greuter MD1, Stephan R. Vavricka MD1,2, and Michael Scharl MD1 
 
1Department of Gastroenterology and Hepatology, University Hospital Zurich, Switzerland 
2Center for Gastroenterology and Hepatology, Zurich, Switzerland 
 
We thank Dr. Eman Al Sulais and colleagues for their interest in our paper on “Malignancies in 
inflammatory bowel disease: Frequency, incidence and risk factors – Results from the Swiss IBD Cohort 
Study”. The authors elegantly underscore the possible impact of family history on cancer development.1 
Positive family history for cancer is a known risk factor for various cancer types in non-IBD patients. 
Studies have shown a two-fold increase for colorectal cancer (CRC) and a 2 to 5-fold increase for pancreatic 
cancer, if a first-line relative suffered from CRC and pancreatic cancer, respectively.2,3 And many more 
cancer types could be mentioned here. We therefore agree that looking at this aspect would be of 
considerable interest. Including it as a co-variable in our multivariate models could answer the looming 
question whether patients with a positive family history are at particular risk if treated with 
immunosuppressive agents such as azathioprine. However, such analysis is not possible since family history 
for cancer – in contrast to family history for IBD – is not captured in the Swiss IBD cohort study (SIBDCS) 
questionnaires. While it might be worthwhile including such a question for future prospective cohort 
projects, retrospective inclusion of family history by addressing all SIBDCS patients would be largely prone 
to a recall bias. This would make it difficult to draw clear conclusions. It has been previously shown that 
reliability of self-reported family history of cancer considerably varies between case patients and controls.4 
We appreciate the continued interest and insightful questions raised by Dr. Al Sulais et al. We are 
looking forward to upcoming cancer analyses in large IBD cohorts, where additional factors (including family 
history of cancer) are taken into account. This will help us to guide our patients when dealing with questions 
regarding IBD- and/or immunosuppression-related cancers.  
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